 Cellular Biomedicine Group, Inc. NASDAQ: CBMG CBMG or the Company, a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on Friday, February 28, 2020. 